SAN DIEGO, May 4, 2011 /PRNewswire/ -- Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept's Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr. Dunn will act as the Senior Vice President, Corporate Development.
"I am very excited about the addition of Lyle and Mike to the Biocept team," said Hale. "Each has significant experience and expertise in the diagnostic field and will provide invaluable insight regarding scientific and business opportunities for Biocept," continued Hale.
Lyle Arnold, PhD
Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering molecular diagnostics, genomics and therapeutics. Dr. Arnold is a founder and director of Aegea Biotechnologies a next generation nucleic acid technology company. Previously he was VP, Research at Gen-Probe from September 2003 to October 2009. He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder). In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He is the principle inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies, core to Gen-Probe assays that have generated more than $5B in product revenue. In addition, he has authored more than 50 scientific publications. Dr. Arnold also serves on the board of directors of Asuragen, a rapidly emerging biotechnology company in Austin, Texas. He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Mike Dunn, MBA
Mr. Dunn assumes the role of Senior Vice President, Corporate Development after serving as a consultant to Biocept for several months. He has 30 years of experience in the diagnostics, pharmaceutical and biotech industries. Prior to Biocept, Mr. Dunn served as Vice President and Chief Business Officer of Monogram Biosciences, a biotech laboratory specializing in infectious disease and cancer diagnostics, which was acquired by LabCorp in 2009. Previously, Mr. Dunn served as Vice President and Chief Business Officer of ACLARA BioSciences, a company specializing in microfluidic chips and cancer diagnosis through its merger with Virologic, Inc., as well as Vice President and Chief Business Officer at ActivX Biosciences, a biopharmaceutical company that utilizes proteomics to discover and develop small molecule drugs for major unmet medical needs. Additionally, Mr. Dunn served as Vice President of Business Development at Aurora Biosciences, a company that developed and commercialized proprietary drug discovery systems, services and technologies prior to its acquisition by Vertex Pharmaceutical in 2001. Mr. Dunn began his biotech career with various project management and business development roles at the Salk Institute Biotechnology/Industrial Associates (SIBIA) and it's successor, SIBIA Neurosciences, culminating as VP of Business Development. SIBIA was acquired by Merck in 1999. Mr. Dunn holds a B.A. in Biology from the University of Chicago and a MBA in Finance from the University of San Diego.
About Biocept, Inc.
Biocept Laboratories, headquartered in San Diego, California, is a diagnostic and advanced laboratory services company specializing in the capture, detection, isolation and molecular analysis of circulating tumor cells (CTCs). Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes patented and innovative technologies to deliver clinically relevant information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with information highly relevant for the treatment of their patients with cancer.
|SOURCE Biocept, Inc.|
Copyright©2010 PR Newswire.
All rights reserved